symowugebeda.blogspot.com
The Franklin-based company (Nasdaq: BMTI) reporte d a net loss of $8 or 43 cents per diluted in the quarter endedMarch 31, compared to earnings of $31.3e million, or $1.62 per diluted share, in the same quartee in 2008. That year-ago period’s performancde included a $39.3 million gain from the sale ofthe company’sa orofacial therapeutics business. Revenue came in at $379,000 for the down 20 percent from theprevious year’s when revenue was excluding the gain from the BioMimetic develops regenerative protein-devicwe combination products to aid in issue healing and regeneration.
Its productsx are used to help heal musculoskeletal injuries and including orthopedic, spine and sports injuries. The compangy has numerous products in various stages of clinicapl trialsor pre-market development. At the bell shares of BioMimetic closedat $8.07, up 2 percent from Wednesday’sx closing price. The 52-week range is $4.69 to $14.09.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment